Corrected: Westlake targets $450M for Seidenberg's next life sciences fund
Life sciences VC firm Westlake Village BioPartners is ready to restock its capital reserves shortly after its success with bringing portfolio company Acelyrin to one of the biggest IPOs in recent biotech memory.
The Los Angeles venture firm — led by well-known ex-Kleiner Perkins investor Beth Seidenberg — eyes a $450 million fund, per a Thursday SEC filing. Westlake’s other founding managing director, former Amgen R&D executive Sean Harper, is not listed on the SEC filing as a participant in the fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.